Shenyang Xingqi Pharmaceutical 兴齐眼药
10 significant filings since 30 May 2026: 9 on buyback and 1 on dividend. The latest, on 15 Sep 2026: 2026年半年度权益分派实施公告.
自 30 May 2026 起有 10 份重大公告：buyback 9 份、dividend 1 份。最新一份（15 Sep 2026）：2026年半年度权益分派实施公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 27 Apr 2020 | 太平洋 | 杜佐远,李蕾 | Buy 买入 | ▼ | Neutral 中性 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 余汝意,阮帅 | Buy 买入 | 30 Aug 2026 | 2 | — |
| 华安证券 | 谭国超,任婉莹 | Buy 买入 | 30 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。